Krystal Biotech, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Krystal Biotech's 2025 annual report highlights significant revenue growth from its gene therapy VYJUVEK, expanded global approvals, and positive clinical progress across its pipeline, while navigating increased operating expenses.
NASDAQ
Krystal Biotech's 2024 10-K filing highlights the successful commercial launch of VYJUVEK, ongoing clinical trials, and strategic expansion initiatives.
NASDAQ
Krystal Biotech's FY2023 results highlight the successful commercial launch of VYJUVEK, the first FDA-approved treatment for dystrophic epidermolysis bullosa (DEB), and continued progress in its gene therapy pipeline.